New research, guidelines and FDA decisions, each with a note on what it might change in a conversation with your surgeon, how certain it is, and links to the original sources.
How we choose news. Nothing here is sponsored. Mentioning a product isn't an endorsement, and an FDA clearance means a device was found substantially equivalent to existing ones, not proven better. Updated November 2026.
Research
Where you have cataract surgery may affect results
A study of nearly 42,000 cataract-operated eyes across 61 countries found poorer visual outcomes after surgery in outreach camps than at fixed facilities, though results improved over time in all settings.
What this could change in a conversation with your surgeon: Results vary between centers. It's reasonable to ask your surgeon how often their patients reach good vision after surgery.
How often is cataract surgery 'successful'? It depends on the bar
Across 16 US health systems, about 91% of eyes saw 20/40 or better within 90 days of surgery, and about 56% saw 20/20. Rates rose slightly by 180 days.
What this could change in a conversation with your surgeon: Ask what vision your surgeon expects for you specifically, especially if you have other eye conditions.
Laser-assisted cataract surgery: no safety edge in new analysis
A meta-analysis of randomized trials presented at the ASCRS 2026 meeting found femtosecond laser-assisted surgery and standard phacoemulsification had equivalent safety.
What this could change in a conversation with your surgeon: It adds to trials showing the laser upgrade doesn't improve results for most people. Ask what it would add in your case before paying extra.
Business, product and professional-society developments. Useful background, but less likely to change your own decision.
Industry
FDA approves TECNIS PureSee extended depth of focus lens
Johnson & Johnson's TECNIS PureSee lens, designed to give good distance and intermediate vision with some near vision, was approved by the FDA. The company says it's the first US EDOF lens without a contrast sensitivity warning. US rollout began in June.
What this could change in a conversation with your surgeon: It's one more premium option. Ask how it compares with standard and multifocal lenses for glare, halos and reading, and what it costs you.